Loading...
Loading...
In a report published Wednesday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Equal-Weight rating on
Charles River LaboratoriesCRL.
In the report, Morgan Stanley noted, “CRL reported 4Q13 EPS of $0.73 vs. cons/MS at $0.68 with beat driven by below the line items. Specifically, sources of upside vs. MS included sales (+$0.01), net int. (+$0.02), other inc. ($0.01), tax rate (+$0.04) and share count (+$0.01), offset by operating margin (-$0.04).”
Charles River Laboratories closed on Tuesday at $57.99.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in